These tools will allow to more efficiently test new brain delivery strategies for next generation therapeutics. They will also allow to identify new pharmacological targets to restore the neuroprotective functions of blood-brain interfaces that are impacted by different CNS diseases. This project benefit from a partnership with Cynbiose and Brain-i, and from a collaboration with the “Biological Analysis by Mass Spectrometry” team of the Analytical Sciences Institute (ISA).